ES2147758T3 - Preparacion sinergistica para la activacion de celulas destructoras naturales. - Google Patents
Preparacion sinergistica para la activacion de celulas destructoras naturales.Info
- Publication number
- ES2147758T3 ES2147758T3 ES93913731T ES93913731T ES2147758T3 ES 2147758 T3 ES2147758 T3 ES 2147758T3 ES 93913731 T ES93913731 T ES 93913731T ES 93913731 T ES93913731 T ES 93913731T ES 2147758 T3 ES2147758 T3 ES 2147758T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- activation
- preparation
- date
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004913 activation Effects 0.000 title abstract 2
- 230000001066 destructive effect Effects 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
UNA PREPARACION FARMACEUTICA O UN SISTEMA PARA LA ACTIVACION DE CELULAS ASESINAS NATURALES (CELULAS NK), PARA, POR EJEMPLO, TRATAR TUMORES O INFECCIONES VIRALES Y QUE CONTIENE UNA PRIMERA COMPOSICION DE INTERFERONES-(ALFA) O DE ANALOGOS DE LOS MISMOS, JUNTO CON UNA SEGUNDA COMPOSICION QUE CONTIENE AL MENOS UNA SUSTANCIA CON H2 O 5-HT1A, UNA ACTIVIDAD AGONISTA RECEPTORA, POR EJEMPLO, HISTAMINA O SEROTININA. LA PRIMERA Y LA SEGUNDA COMPOSICIONES SE PUEDEN BIEN MEZCLAR EN UNA PREPARACION O PRESENTARSE A MODO DE DOSIS INDEPENDIENTES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9201719A SE513429C2 (sv) | 1992-06-03 | 1992-06-03 | Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2147758T3 true ES2147758T3 (es) | 2000-10-01 |
Family
ID=20386405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93913731T Expired - Lifetime ES2147758T3 (es) | 1992-06-03 | 1993-06-03 | Preparacion sinergistica para la activacion de celulas destructoras naturales. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5728378A (es) |
| EP (1) | EP0652768B1 (es) |
| JP (1) | JP2888259B2 (es) |
| AT (1) | ATE192338T1 (es) |
| CA (1) | CA2136952C (es) |
| DE (1) | DE69328558T2 (es) |
| DK (1) | DK0652768T3 (es) |
| ES (1) | ES2147758T3 (es) |
| GR (1) | GR3033894T3 (es) |
| PT (1) | PT652768E (es) |
| SE (1) | SE513429C2 (es) |
| WO (1) | WO1993024144A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063373A (en) | 1989-09-19 | 2000-05-16 | Maxim Pharmaceuticals, Inc. | Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor |
| US6003516A (en) * | 1992-06-03 | 1999-12-21 | Maxim Pharmaceuticals, Inc. | Method for treatment of cancer and infectious disease |
| CA2159091C (en) * | 1993-03-26 | 2006-12-19 | Richard J. Sharpe | Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| JPH10504304A (ja) | 1994-08-08 | 1998-04-28 | マキシム ファーマシューティカルズ，インコーポレイテッド | ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強 |
| AU778012B2 (en) * | 1996-05-14 | 2004-11-11 | Maxim Pharmaceuticals, Inc. | Administration of histamine for therapeutic purposes |
| US6071942A (en) * | 1996-05-14 | 2000-06-06 | Maxim Pharmaceuticals, Inc. | Elevation of circulating blood histamine levels |
| US5961969A (en) * | 1996-05-14 | 1999-10-05 | Maxim Pharmaceuticals, Inc. | Stable circulating histamine levels |
| US6849452B1 (en) * | 1998-03-03 | 2005-02-01 | Institut Gustave Roussy | Methods for activating natural killer (NK) cells and means for carrying out said methods |
| JP2002523378A (ja) * | 1998-08-24 | 2002-07-30 | マキシム ファーマシューティカルズ インコーポレイテッド | Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護 |
| EP0998923A1 (en) * | 1998-10-30 | 2000-05-10 | Basf Aktiengesellschaft | Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias |
| WO2000039098A1 (en) | 1998-12-23 | 2000-07-06 | Maxim Pharmaceuticals, Inc. | Synthesis of histamine dihydrochloride |
| US6498181B1 (en) * | 1999-01-06 | 2002-12-24 | Maxim Pharmaceuticals | Synergistic tumorcidal response induced by histamine |
| US6242473B1 (en) | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| US6153113A (en) | 1999-02-22 | 2000-11-28 | Cobe Laboratories, Inc. | Method for using ligands in particle separation |
| US6354986B1 (en) | 2000-02-16 | 2002-03-12 | Gambro, Inc. | Reverse-flow chamber purging during centrifugal separation |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| IL160928A0 (en) * | 2001-10-19 | 2004-08-31 | Maxim Pharm Inc | Use of histamine to treat liver disease |
| JP4808612B2 (ja) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
| US20050171192A1 (en) * | 2003-12-11 | 2005-08-04 | Gehlsen Kurt R. | Use of histamine to treat bone disease |
| WO2006009975A2 (en) * | 2004-06-22 | 2006-01-26 | Maxim Pharmaceuticals, Inc. | Histamine to treat disorders affecting muscle function |
| EP1712634A1 (en) * | 2005-04-13 | 2006-10-18 | Wittycell SAS | Selection of highly efficient antigen presenting cells for regulating immunity and uses thereof |
| SG166716A1 (en) | 2009-05-14 | 2010-12-29 | Hsiehs Biotech Singapore Pte Ltd | Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect |
| US20160000777A1 (en) * | 2013-02-21 | 2016-01-07 | University Of Rochester | Methods of using histamine receptor agonists and antagonists |
| CN115925920B (zh) * | 2022-08-04 | 2023-07-25 | 瑞因细胞工程科技(广州)有限公司 | 一种基因增强型免疫细胞治疗肝硬化的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| EP0295317A1 (en) * | 1987-06-16 | 1988-12-21 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Pharmaceutical composition for the treatment of tumors |
| US5215744A (en) * | 1987-06-16 | 1993-06-01 | Boehringer Ingelheim Gmbh | Methods for the treatment of tumors |
| US4883661A (en) * | 1987-10-09 | 1989-11-28 | Daly John M | Use of arginine as an lymphokine synergist |
| US5026544A (en) * | 1988-02-16 | 1991-06-25 | Board Of Reagents, The University Of Texas System | Methods and compositions for inhibiting the growth of neoplastic cells |
-
1992
- 1992-06-03 SE SE9201719A patent/SE513429C2/sv not_active IP Right Cessation
-
1993
- 1993-06-03 CA CA002136952A patent/CA2136952C/en not_active Expired - Lifetime
- 1993-06-03 JP JP6500471A patent/JP2888259B2/ja not_active Expired - Fee Related
- 1993-06-03 PT PT93913731T patent/PT652768E/pt unknown
- 1993-06-03 ES ES93913731T patent/ES2147758T3/es not_active Expired - Lifetime
- 1993-06-03 DK DK93913731T patent/DK0652768T3/da active
- 1993-06-03 AT AT93913731T patent/ATE192338T1/de not_active IP Right Cessation
- 1993-06-03 WO PCT/SE1993/000496 patent/WO1993024144A1/en not_active Ceased
- 1993-06-03 US US08/374,787 patent/US5728378A/en not_active Expired - Lifetime
- 1993-06-03 DE DE69328558T patent/DE69328558T2/de not_active Expired - Fee Related
- 1993-06-03 EP EP93913731A patent/EP0652768B1/en not_active Expired - Lifetime
-
2000
- 2000-07-05 GR GR20000401579T patent/GR3033894T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2888259B2 (ja) | 1999-05-10 |
| EP0652768B1 (en) | 2000-05-03 |
| GR3033894T3 (en) | 2000-11-30 |
| DE69328558D1 (de) | 2000-06-08 |
| CA2136952C (en) | 2005-08-09 |
| JPH08502024A (ja) | 1996-03-05 |
| SE9201719L (sv) | 1993-12-04 |
| SE513429C2 (sv) | 2000-09-11 |
| DK0652768T3 (da) | 2000-08-07 |
| CA2136952A1 (en) | 1993-12-09 |
| AU4366093A (en) | 1993-12-30 |
| PT652768E (pt) | 2000-09-29 |
| SE9201719D0 (sv) | 1992-06-03 |
| EP0652768A1 (en) | 1995-05-17 |
| ATE192338T1 (de) | 2000-05-15 |
| WO1993024144A1 (en) | 1993-12-09 |
| AU672610B2 (en) | 1996-10-10 |
| DE69328558T2 (de) | 2001-01-04 |
| US5728378A (en) | 1998-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE192338T1 (de) | Pharmazeutisches präparat zur synergistischen aktivierung natürlicher killerzellen | |
| EP0675708A1 (en) | PHARMACEUTICAL AND DERMOCOSMETIC AGENTS CONTAINING HORSE DECOLOSTRUM. | |
| DE69333023D1 (de) | 3-beta-hydroxylierte natürliche Steroidderivate enthaltende Arzneimittelzusammensetzungen und ihre Verwendung | |
| BR9509897A (pt) | Composição de liberação controlada para um material biologicamente ativo uso da mesma processo para preparação de uma composição de liberação controlada e para administração a mamíferos especialmente ao homem de um material biologicamante ativo e composição para uso como uma composição medicinal nasal | |
| DE59009034D1 (de) | Desodorierende kosmetische mittel. | |
| DK0695171T3 (da) | Lyosfærer indeholdende gonadotropin | |
| ES2010226A6 (es) | Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos | |
| ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
| ATE240721T1 (de) | Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten | |
| CZ64395A3 (en) | Pharmaceutical composition containing antagonist of interleukin-1 receptor | |
| BR9709062A (pt) | Composto, composição farmacêutica, e, uso de um composto. | |
| BR9306345A (pt) | Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune | |
| DE59406938D1 (de) | Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält | |
| DK0633763T3 (da) | Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug | |
| BR9909486A (pt) | Compostos calcilìticos | |
| FR2681784B1 (fr) | Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides. | |
| PT1149910E (pt) | Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus | |
| NO933345D0 (no) | Forbedrede retardsystemer for tidsforsinket frisetting avmedisinske og/eller biologiske aktive bestanddeler fra etdepot-baerermateriale | |
| FI962550A0 (fi) | Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa | |
| NO944214D0 (no) | Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister | |
| BR9814100A (pt) | Composto derivado de amÈnio bis-quaternário, processo para preparar o mesmo, e, composição farmacêutica | |
| NZ234451A (en) | Benzofuran-substituted 2-imidazoline derivatives and pharmaceutical compositions | |
| Corbel et al. | Evidence for bidirectional histamine transport by murine hematopoietic progenitor cells | |
| ATE141248T1 (de) | Neue bis-phenyl-hexene | |
| ES2087178T3 (es) | Disulfato de ws7622a, procedimiento para su preparacion y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 652768 Country of ref document: ES |